Treasure Global Inc Announces Termination of its At-The-Market Offering Program 2-10-2024, 03:30

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

BUSINESSNEXT Unveils GPTNEXT: Revolutionizing Customer Experiences with Generative AI 11-12-2023, 14:00